Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
13
05
2022
accepted:
03
12
2022
pmc-release:
01
02
2024
entrez:
8
2
2023
pubmed:
9
2
2023
medline:
11
2
2023
Statut:
ppublish
Résumé
The objectives of this study were to use electronic health record data from a US national multicenter pediatric network to identify a large cohort of children with CKD, evaluate CKD progression, and examine clinical risk factors for kidney function decline. This retrospective cohort study identified children seen between January 1, 2009, to February 28, 2022. Data were from six pediatric health systems in PEDSnet. We identified children aged 18 months to 18 years who met criteria for CKD: two eGFR values <90 and ≥15 ml/min per 1.73 m2 separated by ≥90 days without an intervening value ≥90. CKD progression was defined as a composite outcome: eGFR <15 ml/min per 1.73 m2, ≥50% eGFR decline, long-term dialysis, or kidney transplant. Subcohorts were defined based on CKD etiology: glomerular, nonglomerular, or malignancy. We assessed the association of hypertension (≥2 visits with hypertension diagnosis code) and proteinuria (≥1 urinalysis with ≥1+ protein) within 2 years of cohort entrance on the composite outcome. Among 7,148,875 children, we identified 11,240 (15.7 per 10,000) with CKD (median age 11 years, 50% female). The median follow-up was 5.1 (interquartile range 2.8-8.3) years, the median initial eGFR was 75.3 (interquartile range 61-83) ml/min per 1.73 m2, 37% had proteinuria, and 35% had hypertension. The following were associated with CKD progression: lower eGFR category (adjusted hazard ratio [aHR] 1.44 [95% confidence interval (95% CI), 1.23 to 1.69], aHR 2.38 [95% CI, 2.02 to 2.79], aHR 5.75 [95% CI, 5.05 to 6.55] for eGFR 45-59 ml/min per 1.73 m2, 30-44 ml/min per 1.73 m2, 15-29 ml/min per 1.73 m2 at cohort entrance, respectively, when compared with eGFR 60-89 ml/min per 1.73 m2), glomerular disease (aHR 2.01 [95% CI, 1.78 to 2.28]), malignancy (aHR 1.79 [95% CI, 1.52 to 2.11]), proteinuria (aHR 2.23 [95% CI, 1.89 to 2.62]), hypertension (aHR 1.49 [95% CI, 1.22 to 1.82]), proteinuria and hypertension together (aHR 3.98 [95% CI, 3.40 to 4.68]), count of complex chronic comorbidities (aHR 1.07 [95% CI, 1.05 to 1.10] per additional comorbid body system), male sex (aHR 1.16 [95% CI, 1.05 to 1.28]), and younger age at cohort entrance (aHR 0.95 [95% CI, 0.94 to 0.96] per year older). In large-scale real-world data for children with CKD, disease etiology, albuminuria, hypertension, age, male sex, lower eGFR, and greater medical complexity at start of follow-up were associated with more rapid decline in kidney function.
Sections du résumé
BACKGROUND
The objectives of this study were to use electronic health record data from a US national multicenter pediatric network to identify a large cohort of children with CKD, evaluate CKD progression, and examine clinical risk factors for kidney function decline.
METHODS
This retrospective cohort study identified children seen between January 1, 2009, to February 28, 2022. Data were from six pediatric health systems in PEDSnet. We identified children aged 18 months to 18 years who met criteria for CKD: two eGFR values <90 and ≥15 ml/min per 1.73 m2 separated by ≥90 days without an intervening value ≥90. CKD progression was defined as a composite outcome: eGFR <15 ml/min per 1.73 m2, ≥50% eGFR decline, long-term dialysis, or kidney transplant. Subcohorts were defined based on CKD etiology: glomerular, nonglomerular, or malignancy. We assessed the association of hypertension (≥2 visits with hypertension diagnosis code) and proteinuria (≥1 urinalysis with ≥1+ protein) within 2 years of cohort entrance on the composite outcome.
RESULTS
Among 7,148,875 children, we identified 11,240 (15.7 per 10,000) with CKD (median age 11 years, 50% female). The median follow-up was 5.1 (interquartile range 2.8-8.3) years, the median initial eGFR was 75.3 (interquartile range 61-83) ml/min per 1.73 m2, 37% had proteinuria, and 35% had hypertension. The following were associated with CKD progression: lower eGFR category (adjusted hazard ratio [aHR] 1.44 [95% confidence interval (95% CI), 1.23 to 1.69], aHR 2.38 [95% CI, 2.02 to 2.79], aHR 5.75 [95% CI, 5.05 to 6.55] for eGFR 45-59 ml/min per 1.73 m2, 30-44 ml/min per 1.73 m2, 15-29 ml/min per 1.73 m2 at cohort entrance, respectively, when compared with eGFR 60-89 ml/min per 1.73 m2), glomerular disease (aHR 2.01 [95% CI, 1.78 to 2.28]), malignancy (aHR 1.79 [95% CI, 1.52 to 2.11]), proteinuria (aHR 2.23 [95% CI, 1.89 to 2.62]), hypertension (aHR 1.49 [95% CI, 1.22 to 1.82]), proteinuria and hypertension together (aHR 3.98 [95% CI, 3.40 to 4.68]), count of complex chronic comorbidities (aHR 1.07 [95% CI, 1.05 to 1.10] per additional comorbid body system), male sex (aHR 1.16 [95% CI, 1.05 to 1.28]), and younger age at cohort entrance (aHR 0.95 [95% CI, 0.94 to 0.96] per year older).
CONCLUSIONS
In large-scale real-world data for children with CKD, disease etiology, albuminuria, hypertension, age, male sex, lower eGFR, and greater medical complexity at start of follow-up were associated with more rapid decline in kidney function.
Identifiants
pubmed: 36754006
doi: 10.2215/CJN.0000000000000051
pii: 01277230-202302000-00008
pmc: PMC10103199
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-182Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Kidney Int. 2021 Apr;99(4):948-956
pubmed: 33301749
Clin J Am Soc Nephrol. 2011 Aug;6(8):1824-30
pubmed: 21737850
Am J Kidney Dis. 2015 Jun;65(6):878-88
pubmed: 25799137
J Am Soc Nephrol. 2016 Feb;27(2):543-50
pubmed: 26139439
Pediatr Nephrol. 2021 May;36(5):1279-1288
pubmed: 33108507
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
J Am Med Inform Assoc. 2014 Jul-Aug;21(4):602-6
pubmed: 24821737
J Pediatr. 2021 Dec;239:5-10.e4
pubmed: 33798511
Clin J Am Soc Nephrol. 2009 Apr;4(4):812-9
pubmed: 19297612
Am J Kidney Dis. 2018 Jun;71(6):783-792
pubmed: 29653769
Semin Nephrol. 2021 Sep;41(5):446-454
pubmed: 34916006
J Am Soc Nephrol. 2019 Dec;30(12):2427-2435
pubmed: 31732612
Clin J Am Soc Nephrol. 2021 Apr 7;16(4):648-659
pubmed: 33177074
Clin J Am Soc Nephrol. 2006 Sep;1(5):1006-15
pubmed: 17699320
Am J Kidney Dis. 2020 Aug;76(2):166-173
pubmed: 32389356
Health Aff (Millwood). 2014 Jul;33(7):1171-7
pubmed: 25006143
Pediatr Nephrol. 2012 Mar;27(3):363-73
pubmed: 21713524
Acad Pediatr. 2018 Jul;18(5):577-580
pubmed: 29496546
Pediatr Nephrol. 2021 Jun;36(6):1551-1559
pubmed: 33200315
N Engl J Med. 2009 Oct 22;361(17):1639-50
pubmed: 19846849
JAMA Netw Open. 2020 Feb 5;3(2):e1921213
pubmed: 32058554
Clin J Am Soc Nephrol. 2011 Sep;6(9):2132-40
pubmed: 21841064
Pediatr Nephrol. 2021 Mar;36(3):527-538
pubmed: 32016626
Am J Kidney Dis. 2018 Nov;72(5):653-661
pubmed: 29784612